'Adjuvant setting' presentation slideshows

Differentiate the Brand

593 views • 50 slides

New Developments in Taxane -based Combinations

446 views • 28 slides

A.D. Roth, R. Biffi, R. Stupp, R. Morant, J.C. Schuller, F. De Braud, O. Huber, N. Fazio

Comparative evaluation in tolerance of neoadjuvant versus adjuvant docetaxel based chemotherapy in resectable gastric cancer in a randomized trial of the Swiss Group for Clinical Cancer Research (SAKK) and the European Institute of Oncology (EIO).

267 views • 17 slides

Current Protocols of the Radiation Therapy Oncology Group

Current Protocols of the Radiation Therapy Oncology Group. Montreal, Quebec Nov. 12, 2004. Phase II Trial (RTOG S-0132): Study Design. R E S E C T I O N. Adjuvant imatinib mesylate (600 mg/d, PO 2 y). SD/PR. Resectable GIST (candidate for neoadjuvant therapy).

280 views • 16 slides

280 views • 1 slides

227 views • 1 slides

Figure 1 The role of PARP inhibitors in synthetic lethality

165 views • 1 slides